ADC Therapeutics SA — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ADC Therapeutics announced a $86.6 million PIPE at $1.42/share (common) and $1.324/pre-funded warrant, with 12.9M shares and 48.1M pre-funded warrants. Simultaneously, it amended its HealthCare Royalty agreement (eliminating $150M change-of-control payment, capping third-party debt at $50M) and refinanced its senior loan (reducing principal from $120M to $50M, eliminating amortization and minimum liquidity covenant). Placement agents: Jefferies, Guggenheim, Cantor. Closing expected October 22, 2026.
Why this rating
Large relative to company size (~$136M market cap). $86.6M gross proceeds (est. $76.3M net) plus removal of $150M contingent payment and debt reduction materially strengthen balance sheet and extend runway. Positive structural improvement.
Tradability signal
NO TRADE
No trade: positive news with only -2.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.01% over 4 hrs, n=227). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.82 ▼ 0.27% | at our read · unknown $1.82 | +10 min · unknown $1.77 ▼ 2.79% | +30 min · unknown $1.69 ▼ 7.40% | +1 hr · unknown $1.71 ▼ 6.58% | +4 hrs · unknown $1.71 ▼ 6.36% |
The stock had already moved +0.27% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.